Current T2DM treatments, such as GLP-1 receptor agonists, effectively lower blood glucose (HbA1c reductions of 0.8–1.5%) and reduce cardiovascular events by up to 12% in high-risk patients [55]. Here, GLP1R is linked to type 2 diabetes mellitus.